Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication

  • Posted on: 28 February 2015
  • By: admin

 

Magazine Home


MAR 2015 ARTICLE LIST >>

PharmaTutor (March- 2015)

 

Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 3, Issue 3)

 

Received On: 24/01/2015; Accepted On: 30/01/2015; Published On: 01/03/2015

 

AUTHORS: Amarjeet Singh*, Sudeep bhardwaj, Ashutosh aggarwal
Department of Pharmacology,
Seth G. L. Bihani S. D. College of Technical Education,
Institute of Pharmaceutical Sciences & Drug Research
amarjeetsingh024@gmail.com

 

ABSTRACT: Objective: The purpose of this study was to examine the risk assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication.
Material & Method: In the present study total 30 patient with essential hypertension of both sex with mean age (48.6±0.8313) were recruited as per the inclusion criteria. Patients were segregated on the behalf of therapy they were using. 22 patients were on Losartan+HCTZ therapy and 8 patients were on Atenolol therapy.
Result: After six month of antihypertensive therapy Atenolol group showing a significant difference in their blood glucose (0.0014) whereas in Losartan+HCTZ group significant difference was not observed (0.1542). Patients of Atenolol group when compared with patient of Losartan+HCTZ group a significant difference was observed in the serum cholesterol level (0.0290).
Conclusion: We found that the use of β-blocker was independently associated with increased risk of type 2 diabetes. So increase in blood glucose in the Atenolol group patient revealed a significant association between use of Atenolol therapy and metabolic dysfunction whereas in Losartan+HCTZ group significant increase in blood glucose was not observed and from these we can conclude therapy with Losartan+HCTZ therapy not associated with metabolic dysfunction.

 

How to cite this article: A Singh, S bhardwaj, A Aggarwal; Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication; PharmaTutor; 2015; 3(3); 41-48

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML]